Compare SYNX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYNX | XBIO |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Israel | United States |
| Employees | N/A | 2 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.5M |
| IPO Year | 2023 | N/A |
| Metric | SYNX | XBIO |
|---|---|---|
| Price | $1.01 | $3.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 221.5K | 25.1K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.35 | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.90 |
| 52 Week High | $2.15 | $13.93 |
| Indicator | SYNX | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 63.23 |
| Support Level | $0.93 | $2.59 |
| Resistance Level | $1.31 | $3.49 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 33.35 | 87.69 |
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.